

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



杭州啓明醫療器械股份有限公司
Venus Medtech (Hangzhou) Inc.

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2500)

**APPLICATION FOR THE FULL CIRCULATION OF SHARES
BY THE COMPANY**

This announcement is made by Venus Medtech (Hangzhou) Inc. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the Announcement [2019] No. 22 “Guidelines for the ‘Full Circulation’ Application for Domestic Unlisted Shares of H-share Listed Companies” (《H股公司境內未上市股份申請「全流通」業務指引》) (the “**Guidelines**”) issued by the China Securities Regulatory Commission (the “**CSRC**”) on November 14, 2019 regarding the procedures to apply for full circulation of shares by companies whose H shares are listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

In view of the promulgation of the Guidelines, the board of directors (the “**Board**”) of the Company is pleased to announce that the Company has submitted an application (the “**Application**”) to the CSRC on June 15, 2020 in respect of the conversion of certain of its domestic shares and unlisted foreign shares (collectively, the “**Unlisted Shares**”) into H shares (the “**H Shares**”) of the Company. Subject to obtaining all the relevant approvals (including the approvals from the CSRC and the Stock Exchange) and the compliance with all the applicable laws and regulations, such Unlisted Shares shall be converted into H Shares and be eligible to be listed and traded on the Main Board of the Stock Exchange. Pursuant to the articles of association of the Company, no further shareholders’ approval of the Company will be required for the conversion of such Unlisted Shares into H Shares.

As at the date of this announcement, the Company has not received approval from the CSRC in respect of the Application. The Company will make further announcements on the progress and details of the Application as and when appropriate.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Venus Medtech (Hangzhou) Inc.
Min Frank Zeng
Chairman

Hangzhou, June 15, 2020

As at the date of this announcement, the executive Directors are Mr. Min Frank Zeng, Mr. Zhenjun Zi and Mr. Lim Hou-Sen (Lin Haosheng); the non-executive Director is Ms. Nisa Bernice Wing-Yu Leung; and the independent non-executive Directors are Mr. Ting Yuk Anthony Wu, Mr. Wan Yee Joseph Lau and Mr. Chi Wai Suen.